| Register
| Log out
Submit An Article

Opinion

Latest Articles

  • Getting taught a lesson from Doctor Copper

    Getting taught a lesson from Doctor Copper

    The term 'Doctor Copper’ has been used as market lingo for decades because of its ability to predict swings and turning points in global markets. In this episode, Tim and Sam dive into the correlation between inflation-adjusted GDP and global Copper Prices to get an overall view on the health of the economy, and toRead More
    Public
  • The FED plays a dangerous game

    The FED plays a dangerous game

    Markets have been wholloped in the last few weeks as investors braced for any optimism from the central bank.  Currently, the FED is playing a dangerous game with their most recent rate hike. Trying to make moves to get inflation under control to bring a glimmer of hope back into the eyes of investors andRead More
    Public
  • The big shift in asset prices – Where to from here?

    The big shift in asset prices – Where to from here?

    Investors in the past week, no doubt, would have come across a torrent of news reports on the selloff in global share markets, rising inflation & interest rates, and energy shortages on the east coast of Australia with a real possibility of ongoing blackouts. Therefore, investors can be forgiven for feeling a little anxious about

    Read More
    Public
  • Why Orthocell has blown my mind this morning

    Why Orthocell has blown my mind this morning

    When I read Orthocell’s (ASX: OCC) company announcement I had to do a double take.  Why?  Because they are casually RESTORING FUNCTION TO PARALYSED LIMBS. Go back, read that again. Scoop your jaw off the floor.  That’s right, regenerative medicine company Orthocell (ASX: OCC) has received final data for their nerve reconstruction study were theyRead More
    Public
  • The ASX listed biotech companies making their mark in oncology

    The ASX listed biotech companies making their mark in oncology

    Balance sheets don’t tell the whole story. This is especially true for biotech companies where pre-revenue businesses can still be worth billions of dollars with the innovative medicines they are creating.  On a macro level, biotech companies outperformed the S&P 500 and both pharmaceutical and medtech sectors in terms of total returns to shareholders overRead More
    Public
  • Pass go, collect mortgage: Why the Government’s latest first home buyer’s scheme is crap

    Pass go, collect mortgage: Why the Government’s latest first home buyer’s scheme is crap

    “Sorry, but what the f**k is the point of a first home buyers scheme if we need another first home buyers scheme to access it?” That was the question that came out of my best friend’s mouth whilst we waited for our post-pilates morning lattes today. It’s been bouncing around in my brain as IRead More
    Public

Login or register for free to access unlimited reading

Register Now!

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.